CAMBRIDGE, Mass.—At the recent meeting of the American Association for Cancer Research, AVEO Pharmaceuticals announced the development of the first platform for the generation of fully human breast tumors in mice. According to company scientists, the Human-in-Mouse (HIM) system is a significant improvement over current xenograph models of human breast cancer and should facilitate more realistic efficacy studies in preclinical drug testing.
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Loading Next Article...
Loading Next Article...


Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe